Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025 – In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Watch the episode

Oncopeptides presented at Stora Aktiedagarna Stockholm

March 12, 2025 – Oncopeptides’ CEO Sofia Heigis recently presented the company at the Aktiespararna event Stora Aktiedagarna in Stockholm, Sweden. The presentation was followed by a Q&A with the moderator from Aktiespararna.

Read more and watch the presentation – in Swedish only.

CEO Sofia Heigis - Oncopeptides AB

Released February 27, 2025

Oncopeptides publishes year-end report 2024

Read report

Download

35% percent quarterly growth, Italian reimbursement and alignment on regulatory pathway in Japan

CEO Sofia Heigis

 

See the Webcast

The presenation in PDF

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Company news

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Regarding recent media attention

February 4, 2025

On Friday, January 31, the Danish Medicines Council, an independent council that produces recommendations and guidelines on medicines for the country's five regions, published a decision to recommend a restriction on the use of the drug lenalidomide.

Read more

Science news

Strong real-world efficacy and safety data with Pepaxti published in the European Journal of Haematology

February 25, 2025

Oncopeptides AB today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology.

Read more

Oncopeptides invited to present at ASH in December

November 20, 2024

Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.

Read more

First patient enters real-world data study in Germany

July 22, 2024

Oncopeptides recently announced entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients.

Read more

Investor news

Oncopeptides presented at Stora Aktiedagarna Stockholm

March 12, 2025

Oncopeptides’ CEO Sofia Heigis recently presented the company at the Aktiespararna event Stora Aktiedagarna in Stockholm, Sweden. The presentation was followed by a Q&A with the moderator from Aktiespararna.

Read more

CEO Sofia Heigis interviewed by Redeye

February 28, 2025

Read more

Invitation to presentation of the year-end report 2024

February 20, 2025

Oncopeptides AB will publish the report for the fourth quarter and the 2024 year-end report, at 08:00 CET on February 27, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET.

Read more

Press release - March 11, 2025

Oncopeptides receives first order of Pepaxti in Italy

Read press release

Upcoming events

2025-04-15 - 2025-05-14

Silent period

Other

2025-04-28

Annual Report 2024

Report

2025-05-15

Interim Report Q1 2025

Report

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Oncopeptides via e-mail